Significant Improvements in DNA Yield From Challenging Forensic Samples Reported...

Significant Improvements in DNA Yield From Challenging Forensic Samples Reported
With Pressure Cycling Technology (PCT)

SOUTH EASTON, Mass., Oct. 21, 2009 (GLOBE NEWSWIRE) -- Pressure BioSciences,
Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that scientists
from the University of North Texas Health Science Center at Fort Worth, Texas
("UNTHSC") reported notable improvements in the yields of DNA from challenging
forensic samples -- such as human hair and bone samples -- when the Company's
pressure cycling technology ("PCT") was added to the DNA extraction workflow, as
compared to the workflow without PCT.

Data were presented by two UNTHSC scientists at the 20th International Symposium
on Human Identification on October 14th in Las Vegas, Nevada. Dr. Suzanne
Gonzalez, R&D lab manager at the UNT Center for Human Identification ("UNTCHI"),
gave an oral presentation entitled "Pressure Cycling Technology (PCT)
Applications for DNA Extractions from Challenging Forensics Samples." In
addition, Ms. Elizabeth Feller, a research scientist at UNTCHI, presented a
scientific poster entitled "DNA Extraction from Hair Using Pressure Cycling
Technology."

Dr. Suzanne Gonzalez, co-principal investigator of the two studies, commented:
"Our results indicate that PCT extraction followed by DNA purification offers an
excellent enhancement to conventional extraction procedures. Potential benefits
include increased DNA yield, reduced processing time, cost reduction, and the
elimination of hazardous organic reagents used in most common extraction
techniques for challenged forensic samples."

Dr. Bruce Budowle, Executive Director of the Institute of Investigative Genetics
at UNTHSC, said: "We conducted an evaluation of PCT's ability to extract DNA
from a variety of forensic samples. Our data show that this novel extraction
method can increase the amount of DNA recovered for downstream analysis from
forensic samples, including aged, degraded, damaged, inhibited, or otherwise
challenging samples. Importantly, PCT has the concomitant benefit of decreasing
both labor time and consumables cost required for DNA analysis. Based on these
findings, we believe that PCT can be a valuable tool in the repertoire to
augment the DNA typing workflow."

Dr. Nathan Lawrence, VP of Marketing at PBI, commented: "UNTHSC -- a leading,
well-respected forensics center -- is led by one of the nation's top
investigative forensic scientists, Dr. Art Eisenberg. We are thrilled that
UNTCHI chose to evaluate the efficacy of PCT when added to DNA extraction
procedures. We believe that the data they generated are both significant and
compelling, and clearly show the advantages of adding PCT to the DNA typing
workflow. We are honored that Dr. Eisenberg and his team chose to present these
exciting data at such an important, international forensics meeting."

Mr. Richard T. Schumacher, President and CEO of PBI, added: "We believe that
these data, when combined with recent results from other leading laboratories,
strongly suggest that PCT can be a valuable addition to the workflow of the DNA
typing laboratories of crime labs, forensic companies, academic institutions,
and research facilities. We believe that there are over 1,000 such laboratories
worldwide. We have initiated a plan to get the UNTHSC data and other information
on the advantages of PCT to these labs over the coming months. This plan
includes discussions with potential distribution partners, which have already
begun. We believe that the widespread dissemination of this information will
result in a measurable increase in sales of our PCT products in the forensics
area in the short and long-term."

About the International Symposium on Human Identification

With an average attendance of well over 650 people, the annual International
Symposium on Human Identification provides a forum for sharing information on
new or improved forensic applications and methods with scientists, crime labs,
other professionals, and forensic companies involved in the field of DNA typing
from around the world.

About the University of North Texas Center for Human Identification

The University of North Texas Center for Human Identification ("UNTCHI") is one
of the leading investigative forensics laboratories in the world. As part of
their mission, scientists at UNTCHI evaluate the most advanced DNA, forensic,
and anthropological tools available for the identification of missing persons
and human remains. They also investigate, validate, and report on the overall
performance of cutting-edge DNA typing and other forensic procedures and
technologies to help bring the next generation of new, valuable tools to
forensic testing laboratories. Such tools are invaluable for solving crimes
(including homicides and sexual assaults), and for solving cold and missing
person cases.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the
development of a novel, enabling technology called Pressure Cycling Technology
(PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high
levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI
currently holds 13 US and 6 foreign patents covering multiple applications of
PCT in the life sciences field, including genomic and proteomic sample
preparation, pathogen inactivation, the control of chemical (primarily
enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently
focuses its efforts in the development and sale of PCT-enhanced enzymatic
digestion products designed specifically for the mass spectrometry marketplace,
as well as sample preparation products for biomarker discovery, soil and plant
biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions,
hopes, beliefs, expectations, or predictions of the future are "forward-looking"
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements regarding the use,
capabilities, and benefits of the Company's Pressure Cycling Technology Sample
Preparation System (PCT SPS) for the extraction of DNA from challenging forensic
samples; that PCT offers advantages in the extraction of DNA over conventional
extraction procedures, including benefits in quality, speed, cost, and utility;
the potential for PCT to be a valuable tool for DNA typing; that the data
generated by UNTCHI is both significant and compelling; that there are over
1,000 forensic labs worldwide; and that the dissemination of the data will
result in increased sales of PCT products. These statements are based upon the
Company's current expectations, forecasts, and assumptions that are subject to
risks, uncertainties, and other factors that could cause actual outcomes and
results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are not
limited to: possible difficulties or delays in the implementation of the
Company's strategies that may adversely affect the Company's continued
commercialization of PCT and its PCT-dependent products; changes in customer's
needs and technological innovations; other forensic scientists may not achieve
the same results with PCT reported by the scientists at UNTCHI; and the
Company's sales force may not be successful in selling the Company's PCT product
line because scientists may not perceive the advantages of PCT over other sample
preparation methods, including in the investigative forensics area. Further, the
Company expects that it will need additional capital to fund its continuing
operations beyond the second quarter of 2010. Additional risks and uncertainties
that could cause actual results to differ materially from those indicated by
these forward-looking statements are discussed under the heading "Risk Factors"
in the Company's Annual Report on Form 10-K for the year ended December 31,
2008, and other reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information included in
this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

-0-
CONTACT: Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
R. Wayne Fritzsche, Chairman
(508) 230-1828